文献速递外周动脉疾病

药物涂层球囊在自体静脉外周-远端旁路移植血管维护中的应用:进展与潜在影响

Drug-Coated Balloons in Autologous Vein Peripheral-Distal Bypass Graft Maintenance: Advancements and Potential Impact.
PubMed 文献 · J Endovasc Ther · 2024-12-26

该回顾性多中心队列研究纳入2010年1月至2022年12月4家三级血管外科转诊中心连续接受膝下旁路静脉移植物狭窄药物涂层球囊(DCB)血管成形术的患者,共86例(29%)使用紫杉醇涂层球囊。中位随访5年辅助一期通畅率为69%,1年肢体挽救率100%、3年90%,5年总生存率84%。作者认为DCB可能减少重复再干预需求并改善生活质量。

要点

  • 膝下自体大隐静脉旁路移植物狭窄接受DCB血管成形术,中位随访5年辅助一期通畅率为69%。
  • 1年肢体挽救率100%、3年90%;中位随访10年仅记录6例大截肢。
  • DCB术后5年总生存率84%,中位随访9.4年(95%CI 8.7-10.1)计算。

核心结论

  • 结果提示DCB可能对血管诊疗产生变革性影响,减少重复再干预需求,从而改善外周旁路移植物患者的生活质量。

研究设计与样本

  • 回顾性多中心队列研究,纳入2010年1月至2022年12月4家三级血管外科转诊中心连续接受膝下旁路静脉移植物狭窄DCB血管成形术的患者。
  • 共296例患者因既有膝下大隐静脉旁路移植物一期通畅性丧失接受血管内手术,其中86例(29%)使用紫杉醇涂层球囊。
  • 患者平均年龄72(67-75)岁,男性占62%(n=53)。
  • 主要终点为辅助一期通畅率、截肢和死亡,在基线、术后1、3、6个月及之后每6个月评估,随访主要通过经验丰富的独立操作者行双功超声完成。

主要发现

  • 从初次血运重建至DCB再干预的中位时间为2.58年(95%CI 2.31-3.10)。
  • DCB血管成形术涉及近端吻合口20%、移植物51%、远端吻合口33%、流出道区域28%。
  • 中位随访5年(3.93-7.01)辅助一期通畅率为69%。
  • 1年肢体挽救率100%,3年90%;中位随访10年记录6例大截肢。
  • 5年总生存率84%,基于中位随访9.4年(95%CI 8.7-10.1)计算。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Initial surgical revascularization has a recognized primary role in patients with critical limb-threatening ischemia with a high-quality great saphenous vein for conduit. However, approximately one-third of lower extremity vein grafts develop lesions threatening graft patency. Traditional treatments have limitations, highlighting the need for innovative solutions. The advantage of drug-coated balloons (DCBs) in treating native femoropopliteal occlusive disease is well established for its anti-restenotic features. This study evaluates the use of DCBs in maintaining the patency of autologous vein infrainguinal bypass grafts. METHODS: This retrospective multicenter cohort study included consecutive patients who underwent DCB angioplasty of infrainguinal bypass vein graft stenoses from January 2010 to December 2022 in 4 tertiary Vascular Surgery referral Centers. The primary endpoints were assisted primary patency rate, amputation, and death. All endpoints were assessed at baseline, at 1, 3, and 6 months, and every 6 months after the procedure. Follow-up was mainly performed via duplex ultrasound, by hand of an experienced independent operator. RESULTS: In total, 296 patients received an endovascular procedure for primary patency loss of a pre-existing infrainguinal saphenous vein bypass graft. Of these, 86 cases (29%) were treated with a paclitaxel-coated balloon. The mean age of patients was 72 (67-75) years, most being males (62%, n=53). The median time from the primary revascularization to reintervention with DCB was 2.58 (95% confidence interval [CI]: 2.31-3.10) years. The DCB angioplasty involved the proximal anastomosis in 20%, the graft in 51%, the distal anastomosis in 33%, and the outflow region in 28% of cases. During a median follow-up of 5 years (3.93-7.01), a 69% assisted primary patency rate was recorded. Limb salvage was achieved in 100% of cases at 1 year and in 90% of cases at 3 years. Only 6 cases of major amputation were recorded in a median follow-up time of 10 years. Overall survival reached 84% at 5 years, calculated on a median follow-up of 9.4 (95% CI: 8.7-10.1) years. CONCLUSION: Results suggest that DCBs may have a transformative impact on vascular care, reducing the need for repeated reinterventions, and thus improving the quality of life for patients with peripheral bypass grafts.Clinical ImpactThis study proposes a groundbreaking shift in the management of lower extremity vein graft lesions. By demonstrating the efficacy of drug-coated balloons (DCBs) in maintaining patency of infrainguinal vein bypass grafts, it offers clinicians a novel strategy to address a significant clinical challenge. Unlike traditional treatments with their limitations, DCBs present a promising alternative, potentially reducing the burden of repeated reinterventions. This innovation signifies a tangible improvement in patient outcomes, promising enhanced limb salvage rates and overall survival, thereby revolutionizing vascular care and enhancing the quality of life for individuals with peripheral bypass grafts.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Barillà D, Roscitano G, Derone G, et al. Drug-Coated Balloons in Autologous Vein Peripheral-Distal Bypass Graft Maintenance: Advancements and Potential Impact. J Endovasc Ther. 2024. PMID: 39723637. doi:10.1177/15266028241307574

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。